- ETFs that could benefit from COVID-19 treatments and vaccines.
- U.S. and Europe take different paths on stimulus.
- Jobless claims on the rise.
Monday, July 27, 2020 – Stocks edged lower and long-term bond yields sunk to near record lows, as mounting economic and geopolitical worries spurred a broad risk-off rally this week. Sentiment was initially buoyed by a series of positive developments, namely a rebound in existing home sales, encouraging vaccine trial results and a historic EU fiscal stimulus program that will bring the member countries towards their deepest level of economic cooperation ever. Yet, this encouraging news, that briefly sent the S&P 500 into positive territory for 2020, was summarily snapped towards the end of the week.
On the economic front, U.S. initial jobless claims rose last week for the first time since March, raising fears that the emerging economic recovery could be in peril. These economic concerns were compounded by uncertainty over the renewal of U.S. fiscal stimulus, which has been integral to the stabilization and subsequent economic rebound since the rapid plummet towards recession in March. Critical relief measures from Congress's initial stimulus package, including unemployment benefits, small business loans, mortgage and rental forbearances are set to expire at the end of the July. With the coronavirus pandemic showing no signs of abating, the failure to extend these benefits could have a devastating impact on our economic rebound and general consumer sentiment. Adding to the downward pressure on market sentiment was the tit-for-tat closures of consulates in the U.S. and China. This follows a pattern of sharpening U.S.-Sino tensions, which raises another obstacle to the global economic recovery.
For the week, the DJIA, S&P, and Nasdaq shed 0.8%, 0.3%, and 1.3% respectively. This snapped two and three week winning streaks for the DJIA and S&P 500. Underscoring this week's risk-off rally, the U.S. 10 Treasury dropped to 0.58% and gold rose to a new record price of $1,897.50 a troy ounce.
ETFG Weekly Select List - The five most highly rated ETFs per Sector, Geographic Region and Strategy as ranked by the ETFG Quant model.
Given that the development of a COVID-19 vaccine currently wields an outsize influence on market sentiment, we'd like to highlight ETFs from the health care sector that our model currently favors. The following five 5, ranked 1-5 according to our model, could offer upside exposure towards COVID-19 therapeutics and vaccine progress - SPDR S&P Biotech ETF (XBI), Loncar Cancer Immunotherapy ETF (CNCR), iShares Nasdaq Biotechnology ETF (IBB), VanEck Vectors Biotech ETF (BBH), and VanEck Vectors Pharmaceutical ETF (PPH).
Thanks for reading ETF Global Perspectives!
ETFG 21 Day Free Trial: Sign Up
Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. ETF Global LLC (“ETFG”) and its affiliates and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively ETFG Parties) do not guarantee the accuracy, completeness, adequacy or timeliness of any information, including ratings and rankings and are not responsible for errors and omissions or for the results obtained from the use of such information and ETFG Parties shall have no liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of such information. ETFG PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE.
In no event shall ETFG Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the information contained in this document even if advised of the possibility of such damages.
ETFG ratings and rankings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities or to make any investment decisions. ETFG ratings and rankings should not be relied on when making any investment or other business decision. ETFG’s opinions and analyses do not address the suitability of any security. ETFG does not act as a fiduciary or an investment advisor. While ETFG has obtained information from sources they believe to be reliable, ETFG does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income.
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.